9966 Alphamab Oncology HKEX · China

Alphamab Oncology (9966) news

Alphamab Oncology is a public biotech or pharmaceutical company listed on HKEX under the ticker 9966, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Alphamab Oncology news

We have not published a story on Alphamab Oncology yet. When there is news, it will appear here.

Questions about Alphamab Oncology

What is the ticker symbol of Alphamab Oncology?

Alphamab Oncology trades under the ticker 9966 on HKEX.

Where is Alphamab Oncology listed?

Alphamab Oncology is listed on HKEX. Our directory also records these other listings: GETTEX:3NK.

Which country or territory is Alphamab Oncology listed under?

Our directory records Alphamab Oncology under China.

What does Alphamab Oncology do?

Our directory classifies Alphamab Oncology as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Alphamab Oncology?

The ISIN recorded for Alphamab Oncology is KYG0330A1013.

Does aibio.space cover Alphamab Oncology?

aibio.space lists Alphamab Oncology among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Alphamab Oncology?

Companies in our directory listed in the same country and business area as Alphamab Oncology: 3SBio, Beijing SL Pharmaceutical Co., Walvax Biotechnology Co., Medtide, Guangdong Vtr Bio-Tech Co., Jiangsu gdk Biotechnology Co..

Investor discussion: Alphamab Oncology

Members talk about Alphamab Oncology (9966). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Alphamab Oncology, newest first. Each line links the filing it comes from.

Oct 23, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION - EXERCISE OF WARRANT TO SUBSCRIBE FOR PREFERRED STOCK OF PATHOS AI, INC.. Source
May 20, 2026Financings
Share or debt issue: (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES (INCLUDING RESELL OR TRANSFER TREASURY SHARES); (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING. Source
May 20, 2025Financings
Share or debt issue: (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES (INCLUDING RESELL OR TRANSFER TREASURY SHARES); (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Alphamab Oncology's own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 26, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - LATEST RESEARCH UPDATES OF JSKN003 PRESENTED AT THE 2026 ESMO CONGRESS
Oct 26, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - RESULTS OF A PHASE I/II CLINICAL STUDY OF JSKN033 IN PATIENTS WITH CC FOLLOWING FAILURE OF STANDARD TREATMENT WERE PRESENTED AT THE 2026 ESMO CONGRESS AS A RAPID ORAL PRESENTATION
Oct 26, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - LATEST RESEARCH RESULTS OF TWO PHASE III CLINICAL STUDIES OF ANBENITAMAB (KN026) WERE PRESENTED AT THE 2026 ESMO CONGRESS AS LBA ORAL PRESENTATIONS
Oct 23, 2026HKEXnews
DISCLOSEABLE TRANSACTION - EXERCISE OF WARRANT TO SUBSCRIBE FOR PREFERRED STOCK OF PATHOS AI, INC.
Aug 28, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE
Aug 27, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026
Aug 18, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NDA FOR ANBENITAMAB (KN026) AS FIRST-LINE TREATMENT FOR HER2-POSITIVE ADVANCED BREAST CANCER BY THE NMPA
Aug 4, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NDA FOR ANBENITAMAB (KN026) AS NEOADJUVANT TREATMENT FOR HER2+ BREAST CANCER BY THE NMPA
Aug 4, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - TRANSACTIONS WITH PATHOS AI FOR JSKN016
Aug 3, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - APPROVAL FROM CDE FOR JSKN033 TO INITIATE A PHASE III CLINICAL STUDY FOR THE TREATMENT OF CERVICAL CANCER
Jul 14, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ANBENITAMAB (KN026) WAS AGAIN GRANTED BREAKTHROUGH THERAPY DESIGNATION BY THE NMPA
Jun 12, 2026HKEXnews
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 12, 2026
Jun 10, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) AS FIRST-LINE TREATMENT FOR HER2+ ADVANCED BREAST CANCER MET PRIMARY ENDPOINT
Jun 5, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR AND MANAGEMENT
Jun 2, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES OF JSKN016 FOR PRESENTATION AT 2026 ASCO ANNUAL MEETING
Jun 1, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) FOR NEOADJUVANT TREATMENT OF BC WERE PRESENTED AT LBA ORAL PRESENTATION SESSION OF 2026 ASCO ANNUAL MEETING
May 29, 2026HKEXnews
INSIDE INFORMATION ANNOUNCEMENT - ANBENITAMAB INJECTION OBTAINED MARKETING APPROVAL FROM THE NMPA
May 20, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
May 20, 2026HKEXnews
(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES (INCLUDING RESELL OR TRANSFER TREASURY SHARES); (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING
May 13, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE II CLINICAL STUDY OF JSKN033 AS FIRST-LINE TREATMENT OF ADVANCED CERVICAL CANCER

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:9966 on TradingView.

Listing details

Company: Alphamab Oncology
Ticker: 9966
Listing: HKEX
Country or territory: China
Business scope: Biotechnology
ISIN: KYG0330A1013
Other listed symbols: GETTEX:3NK
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction